Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”

Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx by Qianyi Zhou (6196383)

“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”

Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”

Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc by Qianyi Zhou (6196383)

“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”

Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”

Table 1_Natural compounds: new therapeutic approach for inhibition of Streptococcus mutans and dental caries.docx by Milad Kashi (20970953)

“…The attachment inhibition is achieved by decreasing the expression of adhesion factors such as gtfs, ftf, fruA, and gbpB. …”

Table 3_Global, regional, and national epidemiology of congenital heart disease in children from 1990 to 2021.docx by Jiaoli Xu (20871584)

“…</p>Results<p>In 2021, the global prevalence of CHD in children under five years was over 4.18 million, reflecting a 3.4% increase since 1990. CHD-associated mortality decreased by 56.2%, and DALYs declined by 55.7% from 1990 to 2021. …”

Table 1_Antiepileptic drugs and foetal disorders: analysis of 20-year data from the pharmacovigilance center.docx by Zejun Ji (20787176)

“…The risk of foetal disorders associated with combination therapies varied depending on the specific AEDs combination, with some increasing and others decreasing the risk compared to monotherapy.…”

Image 3_Global, regional, and national epidemiology of congenital heart disease in children from 1990 to 2021.tif by Jiaoli Xu (20871584)

“…</p>Results<p>In 2021, the global prevalence of CHD in children under five years was over 4.18 million, reflecting a 3.4% increase since 1990. CHD-associated mortality decreased by 56.2%, and DALYs declined by 55.7% from 1990 to 2021. …”

Table 5_Global, regional, and national epidemiology of congenital heart disease in children from 1990 to 2021.docx by Jiaoli Xu (20871584)

“…</p>Results<p>In 2021, the global prevalence of CHD in children under five years was over 4.18 million, reflecting a 3.4% increase since 1990. CHD-associated mortality decreased by 56.2%, and DALYs declined by 55.7% from 1990 to 2021. …”

Image 2_Global, regional, and national epidemiology of congenital heart disease in children from 1990 to 2021.tif by Jiaoli Xu (20871584)

“…</p>Results<p>In 2021, the global prevalence of CHD in children under five years was over 4.18 million, reflecting a 3.4% increase since 1990. CHD-associated mortality decreased by 56.2%, and DALYs declined by 55.7% from 1990 to 2021. …”

Table 1_Global, regional, and national epidemiology of congenital heart disease in children from 1990 to 2021.docx by Jiaoli Xu (20871584)

“…</p>Results<p>In 2021, the global prevalence of CHD in children under five years was over 4.18 million, reflecting a 3.4% increase since 1990. CHD-associated mortality decreased by 56.2%, and DALYs declined by 55.7% from 1990 to 2021. …”

Table 4_Global, regional, and national epidemiology of congenital heart disease in children from 1990 to 2021.docx by Jiaoli Xu (20871584)

“…</p>Results<p>In 2021, the global prevalence of CHD in children under five years was over 4.18 million, reflecting a 3.4% increase since 1990. CHD-associated mortality decreased by 56.2%, and DALYs declined by 55.7% from 1990 to 2021. …”

Figure 5 from Elraglusib Induces Cytotoxicity via Direct Microtubule Destabilization Independently of GSK3 Inhibition by Josh T. Coats (20321355)

“…Data normalized to the experimental control peak luminescence. Elraglusib increases the soluble tubulin fraction and decreases the insoluble tubulin fraction in stimulated primary human T cells (<b>C</b> and <b>D</b>). …”

Table 2_Global, regional, and national epidemiology of congenital heart disease in children from 1990 to 2021.docx by Jiaoli Xu (20871584)

“…</p>Results<p>In 2021, the global prevalence of CHD in children under five years was over 4.18 million, reflecting a 3.4% increase since 1990. CHD-associated mortality decreased by 56.2%, and DALYs declined by 55.7% from 1990 to 2021. …”

Image 1_Global, regional, and national epidemiology of congenital heart disease in children from 1990 to 2021.tif by Jiaoli Xu (20871584)

“…</p>Results<p>In 2021, the global prevalence of CHD in children under five years was over 4.18 million, reflecting a 3.4% increase since 1990. CHD-associated mortality decreased by 56.2%, and DALYs declined by 55.7% from 1990 to 2021. …”

Table 1_Cytokine dynamics in the blood and cerebrospinal fluid of HIV/AIDS patients with cryptococcal meningitis receiving antifungal therapy.docx by Rui Su (822125)

“…Over 28 days of antifungal treatment, significant decreases in the CSF levels of IL-2 and IL-10 and the plasma levels of IL-10 and IL-4 were observed. …”

Image 2_Endocrine-disrupting effects of environmental BPS and PFOS on human brain organoid development.tiff by Andrea Di Credico (13137135)

“…PFOS exposure coincided with decreased transthyretin expression, suggesting a potential influence on thyroid hormone availability.…”

Image 1_Endocrine-disrupting effects of environmental BPS and PFOS on human brain organoid development.tiff by Andrea Di Credico (13137135)

“…PFOS exposure coincided with decreased transthyretin expression, suggesting a potential influence on thyroid hormone availability.…”

Different types of participants have different responses to exposure to new normative environments: Judgment changes. by Claire Lugrin (21156528)

“…The colors represent the 4 different environments: A+ (Action + , frequent prosocial action) and J+ (Judgment + , strict judgment) are normative environments increasing prosocial actions, and A- (action -, frequent selfish action) and J- (Judgment -, lenient judgments) normative environments decreasing prosocial actions. …”